The company enrolled 90 patients across the United States, Japan and Taiwan, with top-line data expected in Q1 2027 as it pursues out-licensing talks and plans a global Phase 3 study.
Dasher Neuroscience Holdings Inc. said it has finished patient enrollment in a global, multi-center Phase 2 trial of YA-101 for Multiple System Atrophy, a rare and fatal neurodegenerative disease with no approved disease-modifying therapies. The study enrolled 90 participants across sites in the United States, Japan and Taiwan, and top-line clinical data are expected in the first quarter of 2027. The company said it is also pursuing global out-licensing partnerships and preparing a global multi-center Phase 3 trial to speed YA-101 toward potential commercialization as a first-in-class therapy for MSA. YA-101 is described as a New Chemical Entity and a D-amino acid oxidase inhibitor (drug class targeting DAO enzyme). Dasher Neuroscience said the candidate has received Fast Track Designation from the U.S. Food and Drug Administration (U.S. drug regulator) and Orphan Drug Designation from regulators in the U.S., Japan and the European Union.